Aerocrine, a Sweden-listed medical device maker to help people breathe easier, has raised $50m in combined debt and equity, from a consortium including venture capital firm OrbiMed Advisors and Denmark-based foundation Novo.
OrbiMed and Novo are providing $35m of debt, with SKr95m ($15m) of equity from OrbiMed and a number of institutional investors.